Kimball Electronics Hits a High Note in Q4 with Strong Cash Flow and Strategic Investments
Kimball Electronics, a leading global contract electronics manufacturing services (EMS) provider, wrapped up its fiscal year on a high note, reporting strong cash flow and strategic investments in the medical CDMO space. The company's fourth quarter earnings conference call, held on August 13, 2026, provided a glimpse into the company's performance during the period.
According to Ric Phillips, Chief Executive Officer of Kimball Electronics, sales for the quarter were in line with expectations, with adjusted operating income beating estimates. The company also generated strong cash from operations, which was used to pay down debt to its lowest level in over four years. This achievement is a testament to the company's commitment to financial discipline and its ability to navigate the complexities of the global EMS market.
One of the key highlights of the quarter was the performance of Kimball Electronics' medical business, which grew both year-over-year and sequentially. The medical sales were driven by demand for surgical devices, in vitro diagnostics, patient monitoring, and drug delivery, with approximately 30% of these sales occurring in Asia and Europe. This growth trajectory is a direct result of the company's strategic investments in the medical CDMO space, including the build-out of its new medical facility in Indianapolis and the acquisition of Helvoet Polymer Technologies.
The automotive segment also showed signs of life, with net sales declining by 3% compared to the same period last year. However, Poland and Romania reported mid-single-digit increases due to new steering and braking programs, while China was up low single digits. Steering programs continue to be the largest concentration of work for Kimball Electronics in the automotive segment, accounting for approximately 70% of total automotive sales.
Looking ahead, Jana Croom, Chief Financial Officer, provided guidance for fiscal 2027, highlighting organic sales growth and the accretive impact from Helvoet. The company is expecting medical to continue to outpace the other two verticals and represent more than one-third of total company sales in the fiscal year. This objective is a direct result of the company's strategy to balance its portfolio across the markets it serves.
The company's financial results for the quarter showed net sales of $372 million, a 2% decline compared to Q4 last year but a 5% sequential increase with all three vertical markets posting gains over Q3. Geographically, sales were more evenly distributed around the world versus prior periods, with approximately 40% in North America and 30% in both Asia and Europe.
Overall, Kimball Electronics' performance in the fourth quarter demonstrates its ability to navigate the complexities of the global EMS market while executing on its strategic vision. The company's commitment to financial discipline and its focus on growth opportunities in the medical CDMO space position it well for continued success in fiscal 2027.
